HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa.

Abstract
In this study we describe six Italian patients presenting an unusually mild variant of non-Herlitz junctional epidermolysis bullosa associated with a reduced expression of type XVII collagen. All patients are homozygous for a novel nonsense mutation (R795X) within exon 33 of COL17A1 and show a common haplotype, attesting propagation of an ancestral allele within the Italian population. Analysis of patients' COL17A1 transcripts showed the presence of two mRNA species: a normal-sized mRNA carrying mutation R795X that undergoes rapid decay, and a transcript generated by in-frame skipping of exon 33. Patients keratinocytes were shown to synthesize minute amounts of type XVII collagen, which appeared correctly localized along the cutaneous basement membrane. We therefore suggest that the exon 33-deleted COL17A1 splice variant encodes for type XVII collagen molecules that maintain a functional role and account for the mild phenotype of our patients.
AuthorsL Ruzzi, H Pas, P Posteraro, C Mazzanti, B Didona, K Owaribe, G Meneguzzi, G Zambruno, D Castiglia, M D'Alessio
JournalThe Journal of investigative dermatology (J Invest Dermatol) Vol. 116 Issue 1 Pg. 182-7 (Jan 2001) ISSN: 0022-202X [Print] United States
PMID11168815 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Codon, Nonsense
  • RNA, Messenger
  • Collagen
Topics
  • Adult
  • Alternative Splicing
  • Blotting, Northern
  • Codon, Nonsense
  • Collagen (genetics)
  • Epidermolysis Bullosa, Junctional (epidemiology, genetics)
  • Female
  • Haplotypes
  • Humans
  • Italy (epidemiology)
  • Male
  • Middle Aged
  • RNA, Messenger (metabolism)
  • Transcription, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: